The multifaceted activity of VEGF in angiogenesis – Implications for therapy responses
Vascular endothelial growth factor (VEGF) is a key growth factor driving angiogenesis (i.e. the formation of new blood vessels) in health and disease. Pharmacological blockade of VEGF signaling to inhibit tumor angiogenesis is clinically approved but the survival benefit is limited as patients invariably acquire resistance. This is partially mediated by the intrinsic flexibility of tumor cells to adapt to VEGF-blockade. However, it has become clear that tumor stromal cells also contribute to the resistance.
Source: Cytokine and Growth Factor Reviews - Category: Molecular Biology Authors: Stijn Moens, Jermaine Goveia, Peter C. Stapor, Anna Rita Cantelmo, Peter Carmeliet Tags: Mini review Source Type: research
More News: Molecular Biology